Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
22 January, 2019 23:51 IST
Lupin receives nod for generic Nitrofurantoin capsules
Source: IRIS | 12 Jul, 2018, 12.39PM
Comments  |  Post Comment

Lupin's Nitrofurantoin Capsules USP (Macrocrystals), 50 mg and 100 mg is the generic version of Alvogen Malta Operations Macrodantin Capsules, 50 mg and 100 mg. It is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci, Staphylococcus aureus, and certain susceptible strains of Klebsiella and Enterobacter species.



Lupin Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
LIC completes 51% controlling acquisition in IDBI Bank - 22-Jan-2019 10:25
Lupin receives FDA approval for Levothyroxine Sodium Tablets USP - 21-Jan-2019 17:08
Zydus gets tentative approval from USFDA for Esomeprazole Magnesium Delayed-Release - 21-Jan-2019 16:10
SBI witnessed overwhelming response for its USD 1.25 mn bonds issue - 21-Jan-2019 10:57
HDFC Bank Q3 earnings grow 20% to Rs 55.85 bn - 21-Jan-2019 10:54
BHEL and Libcoin in dialogue to build India's first lithium ion factory - 21-Jan-2019 10:32
BHEL to set up solar electric vehicle chargers along Delhi-Chandigarh highway - 21-Jan-2019 10:28
Wockhardt receives USFDA approval for Leukemia drug - 21-Jan-2019 10:20
Ratnamani Metals & Tubes receives order worth Rs 2 bn - 18-Jan-2019 15:59
Aurobindo Pharma to acquire portfolio of oncology injectables products - 18-Jan-2019 13:47
Reliance Ind Q3 earnings up 8.8%; GRM's at USD 8.8/bbl - 18-Jan-2019 13:08
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer